This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


LEO Pharma A/S

Drug Names(s): JTE-052A, JTE052, JTE052A

Description: JTE-052 is an oral JAK inhibitor, which suppresses overactive immune response via inhibition of Janus kinase (JAK) related to immune signal.

Deal Structure: Japan Tobacco and LEO Pharma
In November 2014, LEO Pharma and Japan Tobacco (JT) entered into a licensing agreement, under which LEO Pharma will obtain exclusive rights to further develop, register and market JTs experimental JAK inhibitor, JTE-052, for topical use in dermatological indications worldwide, excluding Japan where JT retains rights. Under the terms of the agreement, LEO Pharma will be responsible for clinical and commercial activities, including manufacturing, outside Japan. JT will receive an upfront payment, development and sales milestone payments as well as royalties based on product sales.

Partners: Japan Tobacco Inc.

JTE-052 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug